QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports First-Quarter Results, Highlights Progress Across Biotech Platform
Oncotelic Therapeutics (OTCQB: OTLC) reported first-quarter 2026 financial results and a corporate update highlighting continued advancement across its oncology, AI-enabled drug development and advanced drug delivery initiatives, including progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform. The company also said it maintained the previously established approximately $388 million fair value of its 45% ownership interest in GMP Biotechnology as of March 31, 2026, while continuing to pursue capital-efficient growth across its diversified biotechnology platform. To view the full press release, visit https://ibn.fm/DTVsF About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…